Last reviewed · How we verify
Seretide Diskus
At a glance
| Generic name | Seretide Diskus |
|---|---|
| Also known as | Physical examination, adverse event (AE) and serious AE assessments, clinical laboratory safety tests (blood and urine), 12-lead electrocardiogram assessment, SERETIDE delivered via a multi-dose dry powder inhaler |
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus® (PHASE3)
- Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler (NA)
- Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD (PHASE4)
- Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs (PHASE1)
- Description of the Ability to Learn How to Handle Inhaler Devices in COPD (PHASE4)
- Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs
- A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |